Conatus Pharmaceuticals Return on Investment 2012-2018 | CNAT
Current and historical return on investment (ROI) values for Conatus Pharmaceuticals (CNAT) over the last 10 years.
| Conatus Pharmaceuticals ROI - Return on Investment Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | LT Investments & Debt | Return on Investment |
| 2018-12-31 | $-0.02B | $0.03B | -59.38% |
| 2018-09-30 | $-0.02B | $0.03B | -53.52% |
| 2018-06-30 | $-0.02B | $0.03B | -46.15% |
| 2018-03-31 | $-0.02B | $0.04B | -42.60% |
| 2017-12-31 | $-0.02B | $0.04B | -41.46% |
| 2017-09-30 | $-0.02B | $0.04B | -63.45% |
| 2017-06-30 | $-0.03B | $0.05B | -80.00% |
| 2017-03-31 | $-0.03B | $0.03B | -96.43% |
| 2016-12-31 | $-0.03B | $0.02B | -107.14% |
| 2016-09-30 | $-0.03B | $0.03B | -82.54% |
| 2016-06-30 | $-0.03B | $0.03B | -72.46% |
| 2016-03-31 | $-0.03B | $0.03B | -64.94% |
| 2015-12-31 | $-0.02B | $0.04B | -63.58% |
| 2015-09-30 | $-0.02B | $0.04B | -61.74% |
| 2015-06-30 | $-0.02B | $0.05B | -62.59% |
| 2015-03-31 | $-0.02B | $0.03B | -59.86% |
| 2014-12-31 | $-0.02B | $0.03B | -71.19% |
| 2014-09-30 | $-0.02B | $0.04B | -46.38% |
| 2014-06-30 | $-0.01B | $0.05B | -52.53% |
| 2014-03-31 | $-0.01B | $0.00B | -74.07% |
| 2013-12-31 | $-0.01B | $0.05B | -37.04% |
| 2013-09-30 | $-0.01B | $0.00B | -285.71% |
| 2013-06-30 | $-0.00B | $0.00B | -114.29% |
| 2013-03-31 | $0.00B | $0.00B | 0.00% |
| 2012-12-31 | $0.00B | $0.01B | 0.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.024B | $0.034B |
| Conatus Pharmaceuticals, Inc. is a biotechnology company. It is focused on developing and commercializing medicines to treat liver disease. The Company is developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. Conatus Pharmaceuticals, Inc. is headquartered in San Diego, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $133.667B | 26.06 |
| Medtronic (MDT) | Ireland | $114.132B | 16.69 |
| Stryker (SYK) | United States | $69.756B | 24.90 |
| Boston Scientific (BSX) | United States | $49.905B | 24.25 |
| Baxter (BAX) | United States | $39.019B | 25.03 |
| Zimmer Biomet Holdings (ZBH) | United States | $25.114B | 16.07 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.786B | 0.00 |
| Canopy Growth (CGC) | Canada | $16.315B | 0.00 |
| ResMed (RMD) | United States | $14.544B | 27.58 |
| Aurora Cannabis (ACB) | Canada | $9.179B | 64.71 |
| Bio-Rad Laboratories (BIO) | United States | $8.795B | 50.45 |
| Perrigo (PRGO) | Ireland | $6.734B | 10.92 |
| Hill-Rom Holdings (HRC) | United States | $6.397B | 19.79 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $4.994B | 0.00 |
| Insulet (PODD) | United States | $4.964B | 1664.20 |
| ICU Medical (ICUI) | United States | $4.636B | 28.71 |
| Haemonetics (HAE) | United States | $4.354B | 38.62 |
| Hutchison China MediTech (HCM) | China | $3.962B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $3.443B | 0.00 |
| Neogen (NEOG) | United States | $3.004B | 48.85 |
| NuVasive (NUVA) | United States | $2.967B | 25.77 |
| Quidel (QDEL) | United States | $2.487B | 22.25 |
| National Vision Holdings (EYE) | United States | $2.276B | 44.77 |
| Aphria (APHA) | $1.957B | 0.00 | |
| HEXO (HEXO) | $1.474B | 0.00 | |
| Phibro Animal Health (PAHC) | United States | $1.338B | 19.24 |
| VAREX IMAGING (VREX) | United States | $1.234B | 24.16 |
| Cardiovascular Systems (CSII) | United States | $1.212B | 870.25 |
| AtriCure (ATRC) | United States | $1.076B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $0.957B | 25.86 |
| Omeros (OMER) | United States | $0.929B | 0.00 |
| PetIQ (PETQ) | United States | $0.865B | 24.76 |
| Cerus (CERS) | United States | $0.831B | 0.00 |
| MacroGenics (MGNX) | United States | $0.820B | 0.00 |
| NanoString Technologies (NSTG) | United States | $0.781B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.725B | 24.66 |
| TG Therapeutics (TGTX) | United States | $0.717B | 0.00 |
| Evolus (EOLS) | United States | $0.708B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.589B | 25.68 |
| Surmodics (SRDX) | United States | $0.584B | 84.94 |
| LeMaitre Vascular (LMAT) | United States | $0.555B | 26.37 |
| Meridian Bioscience (VIVO) | United States | $0.538B | 16.02 |
| Quanterix (QTRX) | United States | $0.515B | 0.00 |
| Insys Therapeutics (INSY) | United States | $0.332B | 0.00 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.329B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.326B | 21.19 |
| BioLife Solutions (BLFS) | United States | $0.302B | 124.61 |
| Vapotherm (VAPO) | United States | $0.287B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.270B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.228B | 0.00 |
| Owens & Minor (OMI) | United States | $0.213B | 2.91 |
| Zynex (ZYXI) | United States | $0.172B | 18.38 |
| Bovie Medical (APYX) | United States | $0.140B | 0.00 |
| Chimerix (CMRX) | United States | $0.138B | 0.00 |
| Fonar (FONR) | United States | $0.128B | 6.85 |
| Chembio Diagnostics (CEMI) | United States | $0.122B | 0.00 |
| Surface Oncology (SURF) | United States | $0.114B | 0.00 |
| United-Guardian (UG) | United States | $0.089B | 20.32 |
| Female Health (VERU) | United States | $0.088B | 0.00 |
| InfuSystems Holdings (INFU) | United States | $0.085B | 0.00 |
| Neurotrope (NTRP) | United States | $0.075B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.069B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.067B | 19.86 |
| GUARDION HEALTH (GHSI) | United States | $0.054B | 0.00 |
| ImmuCell (ICCC) | United States | $0.045B | 0.00 |
| Senestech (SNES) | United States | $0.036B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.031B | 0.00 |
| Myomo (MYO) | United States | $0.021B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.017B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.011B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.007B | 13.00 |
